Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation for Clopidogrel that Received IND Approval

— Leading Specialty CDMO Partners with AcuteBio, LLC to Create a Breakthrough 505(b)(2) Nanomedicine to Improve Acute Care Treatment Modalities with a Gold Standard Medication — NORTH BRUNSWICK, N.J., June 27, 2023 /PRNewswire/ — Ascendia Pharmaceuticals CEO Jim Huang, Ph.D. announces…